Integra LifeSciences
IART
213 hedge funds and large institutions have $3.5B invested in Integra LifeSciences in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 98 increasing their positions, 64 reducing their positions, and 30 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 64
0.42% more ownership
Funds ownership: 88.3% → 88.72% (+0.42%)
4% less capital invested
Capital invested by funds: $3.63B → $3.5B (-$130M)
5% less funds holding
Funds holding: 224 → 213 (-11)
27% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 30
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$111M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$34.9M |
| 4 |
O
OrbiMed
New York
|
+$34.1M |
| 5 |
BlackRock
New York
|
+$24.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$76.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$27.6M |
| 3 |
CCI
Columbus Circle Investors
|
-$21.6M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$19.7M |
| 5 |
Two Sigma Advisers
New York
|
-$15.7M |
IART Hedge Fund Activity: Q3 2017 in Review
213 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q3 2017, worth a combined $3.5B — down 3.6% from $3.63B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of IART and 22 opened new positions — a net loss of 8 holders — while 64 trimmed existing stakes and 98 added.
The largest buyer was Fidelity Investments, adding an estimated $115M. The largest seller was Eagle Asset Management, cutting an estimated $76.3M.
- 213 institutional investors held Integra LifeSciences (IART) as of Q3 2017, down from 224 in Q2 2017.
- Funds reported $3.5B of Integra LifeSciences stock for Q3 2017, down 3.6% quarter-over-quarter.
- 22 funds opened new Integra LifeSciences positions in Q3 2017 and 30 closed out, a net change of -8 holders.
- The largest Integra LifeSciences buyer in Q3 2017 was Fidelity Investments, an estimated $115M added.
- The largest Integra LifeSciences seller in Q3 2017 was Eagle Asset Management, an estimated $76.3M sold.
Based on aggregated 13F filings for Q3 2017.